ALPHARETTA, Ga., Oct. 27, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the second quarter 2025 on Wed., Nov. 5, at 9 a.m. ET. The company will issue a news release detailing its results before the market opens that same day.
The conference call will be hosted by Dave Pacitti, chief executive officer, and Scott Galovan, senior vice president and chief financial officer.
To instantly join the conference call by phone, use the following link to register close to the call start time: https://emportal.ink/3OBYJOf. After registering, the system will call you and automatically connect you to the conference call. Alternatively, you may join the call by dialing 1-646-357-8785 or 1-800-836-8184 and you will be connected to the call by an operator.
A simultaneous webcast of the call and the related presentation will be accessible via the Investors section of the Avanos Medical website, https://avanos.investorroom.com/. The replay will be accessible within two hours of the end of the call and will be available for one week. Alternatively, you may dial 1-646-517-4150 or 1-888-660-6345 and enter passcode 21545 #.
About Avanos Medical, Inc.
Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures, and markets its recognized brands globally and holds leading market positions in multiple product categories. For more information, visit www.avanos.com and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.

| Last Trade: | US$11.67 |
| Daily Change: | -0.25 -2.10 |
| Daily Volume: | 1,245,875 |
| Market Cap: | US$541.720M |
November 05, 2025 September 15, 2025 August 05, 2025 July 31, 2025 | |

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load